CORT002 is Cortendo Invest AB’s follow-up substance for use in patients with Metabolic
Syndrome.
Cortendo Invest AB has initiated the development of a totally new substance for cortisol
inhibition regulation. A new molecule will be structured with a design customized
for Cortendo Invest AB's purpose.
